TOP TEN perturbations for 39442_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39442_at
Selected probe(set): 203583_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39442_at (203583_at) across 6674 perturbations tested by GENEVESTIGATOR:
R547 study 1 (24h) / vehicle (DMSO) treated DU145 cell sample
Relative Expression (log2-ratio):-3.3440275Number of Samples:2 / 4
Experimental | R547 study 1 (24h) |
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:--- | |
Control | vehicle (DMSO) treated DU145 cell sample |
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours. |
oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample
Relative Expression (log2-ratio):-2.5480213Number of Samples:3 / 3
Experimental | oncolytic herpes simplex virus study 2 |
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours. | |
Control | mock infected peripheral nerve sheath tumor (S462) cell sample |
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours. |
echinomycin study 1 / deferoxamine study 5
Relative Expression (log2-ratio):-2.3828964Number of Samples:3 / 3
Experimental | echinomycin study 1 |
Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:--- | |
Control | deferoxamine study 5 |
Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code: |
kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample
Relative Expression (log2-ratio):-2.2952852Number of Samples:2 / 5
Experimental | kidney transplantation study 15 (8 week) |
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH). | |
Control | normal monocyte (CD14+) sample |
CD14+ monocyte samples derived from healthy control subjects. |
conditioned medium study 1 (HS27a) / untreated monocyte (CD14+) sample
Relative Expression (log2-ratio):2.042162Number of Samples:2 / 2
Experimental | conditioned medium study 1 (HS27a) |
CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h. | |
Control | untreated monocyte (CD14+) sample |
Untreated CD14+ monocytes from two different donors. |
conditioned medium study 1 (HS5) / untreated monocyte (CD14+) sample
Relative Expression (log2-ratio):2.015668Number of Samples:2 / 2
Experimental | conditioned medium study 1 (HS5) |
CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h. | |
Control | untreated monocyte (CD14+) sample |
Untreated CD14+ monocytes from two different donors. |
T-cell isolation study 11 / T-cell isolation study 6
Relative Expression (log2-ratio):-1.9217119Number of Samples:2 / 2
Experimental | T-cell isolation study 11 |
CD4+ resting memory T-cell were isolated from peripheral blood buffy coat of healthy donors after storage for 24 hours at 20°C. The cell fraction was first enriched via density gradient centrifugation with LSM 1077 Ficoll and than FACS sorted as CD3+/CD4+/CD45RO+/CD45RA- population. | |
Control | T-cell isolation study 6 |
CD4+ resting memory T-cell were isolated from whole peripheral blood of healthy donors with no delay. The cell fraction was first enriched via density gradient centrifugation with LSM 1077 Ficoll and than FACS sorted as CD3+/CD4+/CD45RO+/CD45RA- population. |
cell cycle inhibition study 1 / untreated A2780 ovarian carcinoma cell sample
Relative Expression (log2-ratio):-1.8324661Number of Samples:3 / 3
Experimental | cell cycle inhibition study 1 |
Human ovarian carcinoma cells (A2780) exposed to 3 micromolar of a cell cycle inhibitor for 6hrs. | |
Control | untreated A2780 ovarian carcinoma cell sample |
Untreated human ovarian carcinoma cells (A2780). |
brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample
Relative Expression (log2-ratio):1.8020334Number of Samples:2 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; p53HCT116) |
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated p53HCT116 cell sample |
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
brefeldin A study 1 (0.5ug/ml; HCT 116) / untreated HCT 116 cell sample
Relative Expression (log2-ratio):1.786047Number of Samples:3 / 3
Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116) |
Human colon carcinoma cell line HCT116 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
Control | untreated HCT 116 cell sample |
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |